Objective: To consider opioid agonist therapy in prisons.
Conclusions: Given the substantial risks of substance misuse by prisoners, long-acting injectable buprenorphine should be adopted as 'best practice' treatment in Australian prison populations.
Keywords: buprenorphine; injectable; long-acting; opioid therapy; prisoners.